New chapter on the horizon for pharma data exclusivity in India

11 May 2015

Though the European Union has been urging India to adopt provisions beyond World Trade Organization's Trade Related Intellectual Property Rights (TRIPS), a new chapter appears to have opened in India over data exclusivity, one that would interest drug multinationals both from the EU and the USA, reports The Pharma Letter’s India correspondent.

A Pesticides (Amendment) Bill is to be introduced by the Indian government in Parliament. The Bill has a small clause - one that would make India’s Intellectual Property (IP) regime TRIPS Plus. The Bill also proposes to introduce data exclusivity for a period of five years.

Officials have indicated that this could be a forerunner to the grant of a similar reprieve for pharmaceuticals. The development may come as a welcome revelation to drug multinationals from the USA and EU, who have been urging for this for a long time, but have constantly been repudiated by Indian lawmakers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK